ALNYLAM PHARMACEUTICALS, INC. Available-for-sale Securities, Equity Securities, Current
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Available-for-sale Securities, Equity Securities, Current of $2.68 million as of 2017-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent · last filed 2018-02-15
- 2017-03-31: Available-for-sale Securities, Equity Securities, Current $2.68M.
- 2016-12-31: Available-for-sale Securities, Equity Securities, Current $9.00M.
- 2016-09-30: Available-for-sale Securities, Equity Securities, Current $13.61M.
- 2016-06-30: Available-for-sale Securities, Equity Securities, Current $13.33M.
| Period end | Available-for-sale Securities, Equity Securities, Current |
|---|---|
| 2017-03-31 | $2.68M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $9.00M 10-K · filed 2018-02-15 |
| 2016-09-30 | $13.61M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $13.33M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $33.93M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $51.42M 10-K · filed 2017-02-15 |
| 2015-09-30 | $38.56M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $64.63M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $99.89M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $94.58M 10-K · filed 2016-02-12 |
| 2014-09-30 | $41.29M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $49.45M 10-Q · filed 2014-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |